Clinical Trial of SARS-CoV-2 mRNA Vaccine in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-31

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a phase I clinical trial. The investigators intent to evaluate the safety, tolerability and preliminary immunogenicity of SARS-CoV-2 mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People

NCT05352867

SARS-CoV-2

COMPLETED PHASE2

A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China

NCT05547243

SARS-CoV-2

UNKNOWN NA

A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

NCT05547256

SARS-CoV-2

UNKNOWN NA

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

NCT05354089

SARS-CoV-2

UNKNOWN PHASE1

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

NCT05939648

SARS-CoV-2

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-dose group, 18-59 years of age

The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.

Group Type OTHER

Low-dose of LVRNA009

Intervention Type BIOLOGICAL

25μg/person

Placebo

Intervention Type OTHER

0.5ml/person

Middle-dose group, 18-59 years of age

The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.

Group Type OTHER

Middle-dose of LVRNA009

Intervention Type BIOLOGICAL

50μg/person

Placebo

Intervention Type OTHER

0.5ml/person

High-dose group, 18-59 years of age

The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.

Group Type OTHER

High-dose of LVRNA009

Intervention Type BIOLOGICAL

100μg/person

Placebo

Intervention Type OTHER

0.5ml/person

Low-dose group, over 60 years of age

The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.

Group Type OTHER

Low-dose of LVRNA009

Intervention Type BIOLOGICAL

25μg/person

Placebo

Intervention Type OTHER

0.5ml/person

Middle-dose group, over 60 years of age

The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.

Group Type OTHER

Middle-dose of LVRNA009

Intervention Type BIOLOGICAL

50μg/person

Placebo

Intervention Type OTHER

0.5ml/person

High-dose group, over 60 years of age

The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.

Group Type OTHER

High-dose of LVRNA009

Intervention Type BIOLOGICAL

100μg/person

Placebo

Intervention Type OTHER

0.5ml/person

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low-dose of LVRNA009

25μg/person

Intervention Type BIOLOGICAL

Middle-dose of LVRNA009

50μg/person

Intervention Type BIOLOGICAL

High-dose of LVRNA009

100μg/person

Intervention Type BIOLOGICAL

Placebo

0.5ml/person

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age at the time of the first dose of vaccine: aged 18 to 59 years (including boundary values) in the adult group, \>=60 years old in the older group, regardless of gender;
2. Axillary body temperature is less than 37.3 ℃ on the day of enrollment;
3. Based on the medical history and relevant physical examination and laboratory examination results, the investigator clinically determined that the patient was in good health;
4. Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form.

Exclusion Criteria

1. The subject has a history of SARS-CoV-2 infection, or has a history of contact with SARS-CoV-2 infected persons (nucleic acid test positive) or suspected infected persons within 30 days before screening, or living abroad within 30 days before screening history;
2. Anyone who is allergic to any vaccines, drugs, foods or known excipients (Dlin-MC3-DMA, cholesterol, distearoylphosphatidylcholine, PEG2000-DMG);
3. Have a history of SARS virus infection;
4. Upon questioning, have a history of COVID-19 vaccination, or have received other inactivated vaccines within 14 days before screening, and received live attenuated vaccines within 28 days;
5. Patients have a medical history or family history of epilepsy, convulsions or convulsions, neurological diseases and mental diseases;
6. There are contraindications for intramuscular injection, such as: thrombocytopenia that has been diagnosed, any coagulation disorder or receiving anticoagulant treatment, etc.;
7. The investigator judges that he is known or suspected of having more serious diseases at the same time, including but not limited to: respiratory diseases (tuberculosis, lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), Malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided), or during the active period of acute infection or chronic disease (within 3 days before vaccination);
8. Congenital malformations, developmental disorders, or chronic diseases that the investigator judges are not suitable for participating in this study (such as Downs syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc.), excluding stable diabetes/hypertension );
9. Patients with known immunological impairment or low immunological function diagnosed by the hospital before enrollment, or functional asplenia or splenectomy caused by any situation;
10. There is evidence that they are smokers (smokers \>=10 cigarettes/day), alcoholics (alcohol consumption \>=4 units/day), drug abusers, and those who do not agree to quit smoking or drinking during the trial;
11. Positive SARS-CoV-2 nucleic acid test and/or positive antibody test before the first dose of vaccine, and/or abnormal imaging examination (small patchy shadow and interstitial change, obvious peripheral lung zone, ground-glass shadow, infiltrating shadow, lung consolidation, etc.), and/or decreased lymphocyte count;
12. Female: those who have a positive blood pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within one year; men: whose spouse has a pregnancy plan within one year;
13. Patients have participated in other clinical trials (drugs, biological products or devices) within 3 months before the first dose of vaccine, or plan to participate in other clinical trials during the research period;
14. Patients received immune enhancement or immunosuppressive therapy within 6 months before the first dose of vaccine (continuous oral or instillation for more than 14 days);
15. Patients donated blood \>=400 ml within 28 days before screening, or received whole blood, plasma and immunoglobulin therapy within 6 months before screening;
16. Currently receiving research drug treatment to prevent COVID-19;
17. Patients are taking antipyretic, analgesic and anti-allergic drugs within 3 days before enrollment;
18. The investigator judges that the subjects cannot follow the research procedures, comply with the agreement, or plan to permanently relocate from the area before the end of the research, or plan to leave the local area for a long time during the scheduled visit period;
19. The relevant staff involved in this study or their immediate family members (such as spouses, parents, siblings or children).
20. According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes